TrialFrontiers in immunology2024

Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.

Garyfallia Poulakou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.